ID   NCI-H295R
AC   CVCL_0458
SY   NCI H295R; NCIH295R; H295R; H-295R; H295R-S1
DR   BTO; BTO:0002588
DR   CLO; CLO_0008082
DR   EFO; EFO_0002289
DR   MCCL; MCC:0000355
DR   ArrayExpress; E-MTAB-38
DR   ATCC; CRL-2128
DR   cancercelllines; CVCL_0458
DR   CCRID; 1101HUM-PUMC000256
DR   CCRID; 5301HUM-KCB15009YJ
DR   ChEMBL-Cells; CHEMBL3307998
DR   ChEMBL-Targets; CHEMBL612593
DR   CLS; 300483
DR   Cosmic; 1172633
DR   Cosmic; 1191070
DR   Cosmic; 1622873
DR   Cosmic; 2364101
DR   Cosmic; 2574494
DR   IGRhCellID; NCIH295R
DR   KCB; KCB 2015009YJ
DR   Lonza; 378
DR   Progenetix; CVCL_0458
DR   PubChem_Cell_line; CVCL_0458
DR   Wikidata; Q25323725
RX   PubMed=15541570;
RX   PubMed=18000308;
RX   PubMed=20215515;
RX   PubMed=21924324;
RX   PubMed=22266826;
RX   PubMed=23951072;
RX   PubMed=29371329;
RX   PubMed=33981288;
RX   PubMed=34572026;
RX   PubMed=35563746;
RX   PubMed=35764904;
WW   https://en.wikipedia.org/wiki/H295R
CC   Characteristics: Grows in a medium called Nu-Serum type I.
CC   Doubling time: 25 hours (PubMed=29371329).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Pro (c.133T>C); ClinVar=VCV000017589; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Genome sequenced.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Adrenal gland; UBERON=UBERON_0002369.
ST   Source(s): ATCC; CCRID; CLS
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 13
ST   D16S539: 11
ST   D18S51: 17
ST   D19S433: 13
ST   D21S11: 32.2
ST   D2S1338: 25
ST   D3S1358: 15,16
ST   D5S818: 12
ST   D7S820: 9,12
ST   D8S1179: 13
ST   FGA: 19.2,24
ST   Penta D: 8
ST   Penta E: 5,12
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 17,18
DI   NCIt; C9325; Adrenal cortex carcinoma
DI   ORDO; Orphanet_1501; Adrenocortical carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0456 ! NCI-H295
SX   Female
AG   48Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   PubMed=15541570; DOI=10.1016/j.mce.2003.12.020;
RA   Rainey W.E., Saner K., Schimmer B.P.;
RT   "Adrenocortical cell lines.";
RL   Mol. Cell. Endocrinol. 228:23-38(2004).
//
RX   PubMed=18000308; DOI=10.1677/JOE-07-0166;
RA   Samandari E., Kempna P., Nuoffer J.-M., Hofer G., Mullis P.-E.,
RA   Fluck C.E.;
RT   "Human adrenal corticocarcinoma NCI-H295R cells produce more androgens
RT   than NCI-H295A cells and differ in 3beta-hydroxysteroid dehydrogenase
RT   type 2 and 17,20 lyase activities.";
RL   J. Endocrinol. 195:459-472(2007).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21924324; DOI=10.1016/j.mce.2011.08.041;
RA   Wang T., Rainey W.E.;
RT   "Human adrenocortical carcinoma cell lines.";
RL   Mol. Cell. Endocrinol. 351:58-65(2012).
//
RX   PubMed=22266826; DOI=10.1055/s-0031-1298019;
RA   Wang T., Rowland J.G., Parmar J., Nesterova M., Seki T., Rainey W.E.;
RT   "Comparison of aldosterone production among human adrenocortical cell
RT   lines.";
RL   Horm. Metab. Res. 44:245-250(2012).
//
RX   PubMed=23951072; DOI=10.1371/journal.pone.0071022;
RA   Nishi H., Arai H., Momiyama T.;
RT   "NCI-H295R, a human adrenal cortex-derived cell line, expresses
RT   purinergic receptors linked to Ca(2)(+)-mobilization/influx and
RT   cortisol secretion.";
RL   PLoS ONE 8:E71022-E71022(2013).
//
RX   PubMed=29371329; DOI=10.1530/ERC-17-0447;
RA   Kiseljak-Vassiliades K., Zhang Y., Bagby S.M., Kar A., Pozdeyev N.,
RA   Xu M., Gowan K., Sharma V., Raeburn C.D., Albuja-Cruz M.B., Jones K.L.,
RA   Fishbein L., Schweppe R.E., Somerset H., Pitts T.M., Leong S.,
RA   Wierman M.E.;
RT   "Development of new preclinical models to advance adrenocortical
RT   carcinoma research.";
RL   Endocr. Relat. Cancer 25:437-451(2018).
//
RX   PubMed=33981288; DOI=10.3389/fendo.2021.669426;
RA   Rossini E., Tamburello M., Abate A., Beretta S., Fragni M.,
RA   Cominelli M., Cosentini D., Hantel C., Bono F., Grisanti S.,
RA   Poliani P.L., Tiberio G.A.M., Memo M., Sigala S., Berruti A.;
RT   "Cytotoxic effect of progesterone, tamoxifen and their combination in
RT   experimental cell models of human adrenocortical cancer.";
RL   Front. Endocrinol. 12:669426.1-669426.13(2021).
//
RX   PubMed=34572026; DOI=10.3390/cells10092376;
RA   Wellman K., Fu R., Baldwin A., Rege J., Murphy E., Rainey W.E.,
RA   Mukherjee N.;
RT   "Transcriptomic response dynamics of human primary and immortalized
RT   adrenocortical cells to steroidogenic stimuli.";
RL   Cells 10:2376.1-2376.15(2021).
//
RX   PubMed=35563746; DOI=10.3390/cells11091439;
RA   Sigala S., Bothou C., Penton D., Abate A., Peitzsch M., Cosentini D.,
RA   Tiberio G.A.M., Bornstein S.R., Berruti A., Hantel C.;
RT   "A comprehensive investigation of steroidogenic signaling in classical
RT   and new experimental cell models of adrenocortical carcinoma.";
RL   Cells 11:1439.1-1439.17(2022).
//
RX   PubMed=35764904; DOI=10.1007/s12020-022-03112-w;
RA   Sigala S., Rossini E., Abate A., Tamburello M., Bornstein S.R.,
RA   Hantel C.;
RT   "An update on adrenocortical cell lines of human origin.";
RL   Endocrine 77:432-437(2022).
//